Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171929088> ?p ?o ?g. }
- W2171929088 endingPage "1769" @default.
- W2171929088 startingPage "1764" @default.
- W2171929088 abstract "To investigate the spectrum of ocular involvement, to examine the clinical outcome, and to analyze the influence of treatment in patients with chronic ocular manifestations of Reiter's syndrome (RS) referred to a tertiary care ocular immunology service.Retrospective, noncomparative, interventional case series.Twenty-five patients with RS evaluated at the Ocular Immunology and Uveitis Service of the Massachusetts Eye and Ear Infirmary from 1981 through 2001.Charts of patients were reviewed and data on age, gender, follow-up time, ocular symptoms, extraocular involvement, ocular complications, therapy, and visual acuities were recorded.Visual acuity, ocular complications, disease progression, clinical outcome, and systemic treatment.Twenty-five patients (20 male and 5 female) diagnosed with RS, with a mean age at presentation to our service of 37 years, were studied. The mean follow-up was 48.5 months. Eighty-five percent of patients tested were positive for human leukocyte antigen B27. Sixty-four percent of patients had a positive family history. All patients had oligoarthritis and enthesitis, most commonly affecting the back (56%), Achilles tendon (52%), and sacroiliac joint (24%). Eighty percent had a history of infection, most frequently urethritis (68%). Forty-four percent had a history of mucocutaneous lesions. All patients demonstrated ocular involvement at the time of diagnosis (68% with unilateral and 32% with bilateral disease), 84% had evidence of uveitis, 3% had scleritis, 2% had conjunctivitis, and 1% had pars planitis and iridocyclitis. During follow-up, the ocular complications included conjunctivitis (96%), anterior uveitis (92%), posterior uveitis (64%), keratitis (64%), cataract (56%), intermediate uveitis (40%), scleritis (28%), cystoid macular edema (28%), papillitis (16%), and glaucoma (16%). Systemic treatment for ocular inflammation was initiated in all patients. Ninety-six percent were treated with nonsteroidal anti-inflammatory agents. Eighty-eight percent were treated with corticosteroids, 64% requiring systemic prednisone. Immunosuppressive therapy was initiated in 52% of patients, with all receiving methotrexate. Seven patients required more than one immunosuppressive agent. The mean initial visual acuity was 20/25 in the right eye and 20/30 in the left eye. The mean final visual acuity was 20/25 in the right eye and 20/25 in the left eye.Reiter's syndrome may be associated with chronic recurrent ocular inflammation. Systemic therapy (including immunosuppressive treatment) typically is required to control the ocular inflammation and to prevent progressive visual loss." @default.
- W2171929088 created "2016-06-24" @default.
- W2171929088 creator A5004436339 @default.
- W2171929088 creator A5005828241 @default.
- W2171929088 creator A5020218357 @default.
- W2171929088 creator A5055275806 @default.
- W2171929088 creator A5073077641 @default.
- W2171929088 date "2003-09-01" @default.
- W2171929088 modified "2023-10-10" @default.
- W2171929088 title "Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome" @default.
- W2171929088 cites W1970969213 @default.
- W2171929088 cites W1978164704 @default.
- W2171929088 cites W1985421966 @default.
- W2171929088 cites W1989780539 @default.
- W2171929088 cites W1992712264 @default.
- W2171929088 cites W2009247791 @default.
- W2171929088 cites W2028864638 @default.
- W2171929088 cites W2044795290 @default.
- W2171929088 cites W2075696061 @default.
- W2171929088 cites W2088370025 @default.
- W2171929088 cites W2092587854 @default.
- W2171929088 cites W2112901522 @default.
- W2171929088 cites W2115055153 @default.
- W2171929088 cites W2128563477 @default.
- W2171929088 cites W2151947787 @default.
- W2171929088 cites W2342915742 @default.
- W2171929088 cites W2400213434 @default.
- W2171929088 cites W26779515 @default.
- W2171929088 cites W54944790 @default.
- W2171929088 doi "https://doi.org/10.1016/s0161-6420(03)00620-1" @default.
- W2171929088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13129875" @default.
- W2171929088 hasPublicationYear "2003" @default.
- W2171929088 type Work @default.
- W2171929088 sameAs 2171929088 @default.
- W2171929088 citedByCount "37" @default.
- W2171929088 countsByYear W21719290882013 @default.
- W2171929088 countsByYear W21719290882014 @default.
- W2171929088 countsByYear W21719290882015 @default.
- W2171929088 countsByYear W21719290882016 @default.
- W2171929088 countsByYear W21719290882017 @default.
- W2171929088 countsByYear W21719290882019 @default.
- W2171929088 countsByYear W21719290882021 @default.
- W2171929088 countsByYear W21719290882022 @default.
- W2171929088 crossrefType "journal-article" @default.
- W2171929088 hasAuthorship W2171929088A5004436339 @default.
- W2171929088 hasAuthorship W2171929088A5005828241 @default.
- W2171929088 hasAuthorship W2171929088A5020218357 @default.
- W2171929088 hasAuthorship W2171929088A5055275806 @default.
- W2171929088 hasAuthorship W2171929088A5073077641 @default.
- W2171929088 hasConcept C118487528 @default.
- W2171929088 hasConcept C126322002 @default.
- W2171929088 hasConcept C141071460 @default.
- W2171929088 hasConcept C156662089 @default.
- W2171929088 hasConcept C16005928 @default.
- W2171929088 hasConcept C167135981 @default.
- W2171929088 hasConcept C2776148792 @default.
- W2171929088 hasConcept C2776194053 @default.
- W2171929088 hasConcept C2777077863 @default.
- W2171929088 hasConcept C2778257484 @default.
- W2171929088 hasConcept C2778917330 @default.
- W2171929088 hasConcept C2779134260 @default.
- W2171929088 hasConcept C2779368723 @default.
- W2171929088 hasConcept C2780238520 @default.
- W2171929088 hasConcept C2780366729 @default.
- W2171929088 hasConcept C2781053147 @default.
- W2171929088 hasConcept C2992250680 @default.
- W2171929088 hasConcept C71924100 @default.
- W2171929088 hasConceptScore W2171929088C118487528 @default.
- W2171929088 hasConceptScore W2171929088C126322002 @default.
- W2171929088 hasConceptScore W2171929088C141071460 @default.
- W2171929088 hasConceptScore W2171929088C156662089 @default.
- W2171929088 hasConceptScore W2171929088C16005928 @default.
- W2171929088 hasConceptScore W2171929088C167135981 @default.
- W2171929088 hasConceptScore W2171929088C2776148792 @default.
- W2171929088 hasConceptScore W2171929088C2776194053 @default.
- W2171929088 hasConceptScore W2171929088C2777077863 @default.
- W2171929088 hasConceptScore W2171929088C2778257484 @default.
- W2171929088 hasConceptScore W2171929088C2778917330 @default.
- W2171929088 hasConceptScore W2171929088C2779134260 @default.
- W2171929088 hasConceptScore W2171929088C2779368723 @default.
- W2171929088 hasConceptScore W2171929088C2780238520 @default.
- W2171929088 hasConceptScore W2171929088C2780366729 @default.
- W2171929088 hasConceptScore W2171929088C2781053147 @default.
- W2171929088 hasConceptScore W2171929088C2992250680 @default.
- W2171929088 hasConceptScore W2171929088C71924100 @default.
- W2171929088 hasIssue "9" @default.
- W2171929088 hasLocation W21719290881 @default.
- W2171929088 hasLocation W21719290882 @default.
- W2171929088 hasOpenAccess W2171929088 @default.
- W2171929088 hasPrimaryLocation W21719290881 @default.
- W2171929088 hasRelatedWork W2085110177 @default.
- W2171929088 hasRelatedWork W2290046770 @default.
- W2171929088 hasRelatedWork W2398052703 @default.
- W2171929088 hasRelatedWork W2587819704 @default.
- W2171929088 hasRelatedWork W2605787156 @default.
- W2171929088 hasRelatedWork W3041372178 @default.
- W2171929088 hasRelatedWork W4224231150 @default.
- W2171929088 hasRelatedWork W4243386357 @default.